Eupraxia Pharmaceuticals (TSE:EPR – Get Free Report) was upgraded by equities researchers at Wedbush to a “strong-buy” rating in a report released on Thursday, Zacks reports.
Eupraxia Pharmaceuticals Price Performance
Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biotechnology company developing locally acting therapies designed to improve the delivery, duration and tolerability of established medicines. The company’s platform, DiffuSphere, uses biodegradable polymeric microspheres to provide controlled and sustained drug release at targeted sites in the body.
Read More
- Five stocks we like better than Eupraxia Pharmaceuticals
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
